Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lotus Pharmaceutical CoTPE:1795 +0.27%75 EV-to-FCF is 284.07 as of Sep. 02, 2026, which is 1735% above its 10-year median of 15.48. GuruFocus rates TPE:1795 with a GF Score™ of 75/100 and a GF Value™ of NT$459.23 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 567 Drug Manufacturers companies, Lotus Pharmaceutical Co ranks worse than 94.89% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Lotus Pharmaceutical Co's Enterprise Value is NT$93,126 Mil.
Lotus Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was NT$328 Mil. Therefore, Lotus Pharmaceutical Co's EV-to-FCF for today is 284.07.
The historical rank and industry rank for Lotus Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
TPE:1795'
s EV-to-FCF Range Over the Past 10 Years
Min: -509.17 Med: 15.48 Max: 40745.85
Current: 283.67
During the past 13 years, the highest EV-to-FCF of Lotus Pharmaceutical Co was 40745.85. The lowest was -509.17. And the median was 15.48.
TPE:1795's EV-to-FCF is ranked worse than 94.89% of 567
companies
in the Drug Manufacturers industry
Industry Median: 19.82
vs TPE:1795: 283.67
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lotus Pharmaceutical Co (TPE:1795) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lotus Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Lotus Pharmaceutical Co's share price for today is NT$186.50.
Lotus Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$14.224.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lotus Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Lotus Pharmaceutical Co's EV-to-FCF falls into.
Lotus Pharmaceutical Co's current Enterprise Value is NT$93,126 Mil.
Lotus Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$328 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Pharmaceutical Co (TPE:1795) has a EV-to-FCF of 284.07 as of Sep. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lotus Pharmaceutical Co and its competitors. This is 1735% above median its historical median of 15.48. According to the industry distribution chart, Lotus Pharmaceutical Co ranks #538 out of 567 companies in the Drug Manufacturers industry, placing it in the top 94.9%.
Is Lotus Pharmaceutical Co's EV-to-FCF too high?
Lotus Pharmaceutical Co's current EV-to-FCF of 284.07 is 1735% above median its 10-year median of 15.48. The Drug Manufacturers industry median EV-to-FCF is 19.82. Lotus Pharmaceutical Co's value of 284.07 is 1333.2% above this industry median. Based on the distribution chart, Lotus Pharmaceutical Co ranks #538 out of 567 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lotus Pharmaceutical Co has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lotus Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lotus Pharmaceutical Co ranks #538 out of 567 companies for EV-to-FCF. This places Lotus Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 19.82. Lotus Pharmaceutical Co's value of 284.07 is 1333.2% above this benchmark. While the company's 10-year median is 15.48 vs. the industry median of 19.82, Lotus Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.82, based on 567 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lotus Pharmaceutical Co's current EV-to-FCF of 284.07 is 1333.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Lotus Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Pharmaceutical Co's current EV-to-FCF is 284.07, which is 1735% above median its own 10-year median of 15.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$459.23, compared to a current price of NT$186.50 — trading 59.4% below its estimated fair value. The current EV-to-FCF is 284.07, which is 1735% above median its 10-year median of 15.48 and 1333.2% above the Drug Manufacturers industry median of 19.82. Lotus Pharmaceutical Co's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current EV-to-FCF is 284.07 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$186.50 is trading 59.4% below its estimated GF Value™ of NT$459.23.
GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for TPE:1795:
EV-to-FCF: 284.07 (1735% above median its 10-year median of 15.48)
GF Value™: NT$459.23 vs. price of NT$186.50 (59.4% below fair value)
Industry Position: 1333.2% above the Drug Manufacturers median (#538 of 567)
No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
75GF Score
Get the complete analysis for TPE:1795
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1795 has been successfully added to your 
